Posted by Michael Wonder on 15 Sep 2020
Ziopharm Oncology granted rare paediatric disease designation for controlled IL-12 for the treatment of DIPG
14 September 2020 - -- Ziopharm Oncology today announced that the U.S. FDA has granted rare paediatric disease designation to Ad-RTS-hIL-12 with veledimex (controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma, a lethal brain tumour occurring in the pontine region of the brain.
Diffuse intrinsic pontine glioma accounts for approximately 10 to 15 percent of all cases of brain tumours in children.
The rare paediatric disease designation program is intended to encourage the development of new drugs and biologics for the prevention and treatment of rare paediatric diseases.
